Trusted Resource for Clinical Trials, Protocols & Progress
Sponsors should: (1) establish SOPs for EA requests; (2) train investigators on FDA Form 3926; (3) predefine eligibility criteria; (4) maintain drug supply planning; (5) ensure IRB readiness; (6) document safety reporting rigorously; (7) communicate openly with patients; (8) align EA activities with global access programs; and (9) prepare inspection-ready records of all EA activities.
Click to read the full article.
Sponsors should: (1) assess coverage needs early in trial planning; (2) purchase tailored liability policies; (3) ensure indemnification language in contracts is clear; (4) disclose coverage in informed consent forms; (5) monitor state-specific laws; (6) conduct site audits for compliance; (7) establish claims management procedures; (8) train staff in insurance communication; and (9) maintain ongoing risk reviews throughout the trial lifecycle.
Click to read the full article.
Sponsors should: (1) standardize feasibility questionnaires; (2) pre-negotiate contract templates; (3) prioritize central IRBs; (4) implement electronic submission systems; (5) ensure investigator training early; (6) use risk-based site selection; (7) allocate startup specialists within CRO teams; (8) monitor contract cycle times; (9) maintain transparency with sites; and (10) establish contingency plans for underperforming sites.
Click to read the full article.
Sponsors should: (1) define RBM strategies in monitoring plans; (2) identify critical data elements during protocol design; (3) validate centralized monitoring tools; (4) maintain audit trails of monitoring decisions; (5) train staff across all levels; (6) document risk assessments; (7) combine centralized and on-site monitoring effectively; (8) engage CROs with RBM expertise; (9) conduct pilot studies before full implementation; and (10) ensure inspection readiness through robust documentation.
Click to read the full article.
Sponsors should: (1) validate shipping systems; (2) establish redundant cold chain safeguards; (3) maintain detailed drug accountability logs; (4) ensure chain-of-custody documentation; (5) train site staff; (6) audit vendors regularly; (7) adopt digital monitoring tools; (8) plan contingency stocks; (9) align labeling with FDA and state requirements; and (10) maintain inspection-ready supply records.
Click to read the full article.
Sponsors should: (1) implement robust GCP training programs; (2) strengthen monitoring oversight; (3) ensure real-time documentation; (4) audit CROs and vendors regularly; (5) conduct internal mock inspections; (6) use electronic systems with audit trails; (7) promptly address deviations with CAPA; and (8) maintain inspection readiness at all times.
Click to read the full article.
Investigators should: (1) maintain GCP training; (2) document informed consent rigorously; (3) monitor protocol adherence; (4) ensure contemporaneous documentation; (5) maintain strict IMP accountability; (6) train and supervise staff; (7) engage in mock FDA audits; (8) implement robust CAPA systems; (9) ensure IRB approvals are current; and (10) maintain inspection readiness.
Click to read the full article.
Sponsors should: (1) finalize SAPs before database lock; (2) control multiplicity rigorously; (3) conduct sensitivity analyses; (4) validate datasets and programs; (5) engage statisticians early in protocol development; (6) document randomization and blinding methods; (7) maintain CDISC compliance; (8) train staff in statistical principles; (9) consult FDA on novel designs; and (10) integrate statistical quality assurance into trial oversight.
Click to read the full article.
Sponsors should: (1) align trial protocols globally; (2) plan subgroup analyses in SAPs; (3) ensure GCP compliance across all regions; (4) engage FDA early on MRCT designs; (5) consider bridging studies proactively; (6) diversify global patient enrollment; (7) maintain robust documentation; (8) audit international sites; (9) align statistical analyses with ICH E17; and (10) prepare for cross-agency consultations.
Click to read the full article.
Sponsors should: (1) engage FDA early for orphan designation; (2) design feasible small-sample or single-arm trials; (3) use surrogate endpoints aligned with accelerated approval; (4) partner with patient advocacy groups; (5) ensure GCP compliance at small and large sites; (6) plan post-marketing commitments at trial initiation; (7) utilize global collaborations; (8) integrate biomarkers into eligibility criteria; (9) apply for financial incentives; and (10) maintain inspection readiness.
Click to read the full article.
